Therapeutic potential of synthetic triterpenoids in neuroblastoma

Cancer Biology and Therapy

Volumn 7, Issue 5, 2008, Pages 718-720

  Sun, Shi Yong ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Caspase 8; Neuroblastoma; Triterpenoids

Indexed keywords

2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID; APOPTOSIS INDUCING FACTOR; AZACITIDINE; CASPASE 8; CYTOCHROME C; CYTOKINE; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FENRETINIDE; FLICE INHIBITORY PROTEIN; GAMMA INTERFERON; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAX; RETINOID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; 2-CYANO-3,12-DIOXOOLEAN-1,9-DIEN-28-OIC ACID; DRUG DERIVATIVE; OLEANOLIC ACID; TERPENE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOLOGICAL ACTIVITY; CANCER CELL; CANCER SURVIVAL; CELL DEATH; CELL LINE; CELL TYPE; DRUG ACTIVITY; DRUG SYNTHESIS; GENE DELETION; GENE TRANSFER; METASTASIS; MITOCHONDRION; MORBIDITY; MORTALITY; NEUROBLASTOMA; NOTE; ONCOGENE MYC; OUTCOME ASSESSMENT; SOLID TUMOR; SURVIVAL RATE; THERAPY EFFECT; ANIMAL; BRAIN TUMOR; CELL CYCLE; CHEMISTRY; CYTOSOL; DRUG EFFECT; HUMAN; IC 50; METABOLISM; METHODOLOGY; PROTEIN TRANSPORT; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; CYTOSOL; HUMANS; INHIBITORY CONCENTRATION 50; MITOCHONDRIA; NEUROBLASTOMA; OLEANOLIC ACID; PROTEIN TRANSPORT; TERPENES;

EID: 56149118397     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.5.5903     Document Type: Note

References (39)

1. Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 2007;7: 357-69.
2. Liu J. Oleanolic acid and ursolic acid: research perspectives. Journal of ethnopharmacology 2005;100: 92-4.
3. Dzubak P, Hajduch M, Vydra D, Hustova A, Kvasnica M, Biedermann D, Markova L, Urban M, Sarek J. Pharmacological activities of natural triterpenoids and their therapeutic implications. Natural product reports 2006;23: 394-411.
4. Goldsmith KC, Hogarty MD. Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma. Cancer Lett 2005.
5. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3: 203-16.
6. Ishola TA, Chung DH. Neuroblastoma. Surg Oncol 2007;16: 149-56.
7. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407: 770-6.
8. Konopleva M, Tsao T, Ruvolo P, Stiouf I, Estrov Z, Leysath CE, Zhao S, Harris D, Chang S, Jackson CE, Munsell M, Suh N, Gribble G, Honda T, May WS, Sporn MB, Andreeff M. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 2002;99: 326-35.
9. Kim Y, Suh N, Sporn M, Reed JC. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 2002;277: 22320-9.
10. Alabran JL, Cheuk A, Liby K, Sporn M, Khan J, Letterio J, Leskov KS. Human Neuroblastoma Cells Rapidly Enter Cell Cycle Arrest and Apoptosis Following Exposure to C-28 derivatives of the Synthetic Triterpenoid CDDO. Cancer Biol Ther 2008;7.
11. Zou W, Liu X, Yue P, Zhou Z, Sporn MB, Lotan R, Khuri FR, Sun SY. c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12- dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res 2004;64: 7570-8.
12. Yue P, Zhou Z, Khuri FR, Sun SY. Depletion of intracellular glutathione contributes to JNK-mediated death receptor 5 upregulation and apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me). Cancer Biol Ther 2006;5: 492-7.
13. Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res 2005;65: 4799-808.
14. Zou W, Chen S, Liu X, Yue P, Sporn MB, Khuri FR, Sun SY. c-FLIP downregulation contributes to apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) in human lung cancer cells. Cancer Biol Ther 2007;6: 1614-20.
15. Pedersen IM, Kitada S, Schimmer A, Kim Y, Zapata JM, Charboneau L, Rassenti L, Andreeff M, Bennett F, Sporn MB, Liotta LD, Kipps TJ, Reed JC. The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood 2002;100: 2965-72.
16. Takita J, Yang HW, Bessho F, Hanada R, Yamamoto K, Kidd V, Teitz T, Wei T, Hayashi Y. Absent or reduced expression of the caspase 8 gene occurs frequently in neuroblastoma, but not commonly in Ewing sarcoma or rhabdomyosarcoma. Medical and pediatric oncology 2000;35: 541-3.
17. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000;6: 529-35.
18. Fulda S, Poremba C, Berwanger B, Hacker S, Eilers M, Christiansen H, Hero B, Debatin KM. Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma. Cancer Res 2006;66: 10016-23.
19. Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ho R, Ikegaki N, Brodeur GM. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 2001;61: 1314-9.
20. Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ikegaki N, Brodeur GM. Resistance to TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Medical and pediatric oncology 2000;35: 603-7.
21. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001;20: 5865-77.
22. Stupack DG, Teitz T, Potter MD, Mikolon D, Houghton PJ, Kidd VJ, Lahti JM, Cheresh DA. Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 2006;439: 95-9.
23. Yang Q, Kiernan CM, Tian Y, Salwen HR, Chlenski A, Brumback BA, London WB, Cohn SL. Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin Cancer Res 2007;13: 3191-7.
24. Ikeda T, Nakata Y, Kimura F, Sato K, Anderson K, Motoyoshi K, Sporn M, Kufe D. Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid. Mol Cancer Ther 2004;3: 39-45.
25. Ito Y, Pandey P, Sporn MB, Datta R, Kharbanda S, Kufe D. The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism. Mol Pharmacol 2001;59: 1094-9.
26. Ito Y, Pandey P, Place A, Sporn MB, Gribble GW, Honda T, Kharbanda S, Kufe D. The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. Cell Growth Differ 2000;11: 261-7.
27. Riccioni R, Senese M, Diverio D, Riti V, Mariani G, Boe A, Lococo F, Foa R, Peschle C, Sporn M, Testa U. Resistance of acute myeloid leukemic cells to the triterpenoid CDDO-Imidazolide is associated with low caspase-8 and FADD levels. Leukemia research 2008.
28. Casciano I, Banelli B, Croce M, De Ambrosis A, di Vinci A, Gelvi I, Pagnan G, Brignole C, Allemanni G, Ferrini S, Ponzoni M, Romani M. Caspase-8 gene expression in neuroblastoma. Ann N Y Acad Sci 2004;1028: 157-67.
29. Casciano I, De Ambrosis A, Croce M, Pagnan G, Di Vinci A, Allemanni G, Banelli B, Ponzoni M, Romani M, Ferrini S. Expression of the caspase-8 gene in neuroblastoma cells is regulated through an essential interferon-sensitive response element (ISRE). Cell Death Differ 2004;11: 131-4.
30. Hogarty MD. The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification. Cancer Lett 2003;197: 173-9.
31. Wang Y, Engels IH, Knee DA, Nasoff M, Deveraux QL, Quon KC. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 2004;5: 501-12.
32. Sussman RT, Ricci MS, Hart LS, Sun SY, El-Deiry WS. Chemotherapy- resistant sidepopulation of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. Cancer Biol Ther 2007;6: 1490-5.
33. Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker DT, El-Deiry WS. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 2004;24: 8541-55.
34. Cui H, Li T, Ding HF. Linking of N-Myc to death receptor machinery in neuroblastoma cells. J Biol Chem 2005;280: 9474-81.
35. Sheikh MS. Myc tagging along the TRAIL to death receptor 5. Cell Cycle 2004;3: 920-2.
36. Suh WS, Kim YS, Schimmer AD, Kitada S, Minden M, Andreeff M, Suh N, Sporn M, Reed JC. Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL. Leukemia 2003;17: 2122-9.
37. Bian X, Opipari AW, Jr., Ratanaproeksa AB, Boitano AE, Lucas PC, Castle VP. Constitutively active NFkappa B is required for the survival of S-type neuroblastoma. J Biol Chem 2002;277: 42144-50.
38. Ahmad R, Raina D, Meyer C, Kharbanda S, Kufe D. Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J Biol Chem 2006;281: 35764-9.
39. Yore MM, Liby KT, Honda T, Gribble GW, Sporn MB. The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. Mol Cancer Ther 2006;5: 3232-9.